-

12:31:54 PM

ETON Stock News

ETON - Eton Pharmaceuticals Inc

10/16/20 4:05 PM

Nasdaq : ETON

offeringlow float

Eton Pharmaceuticals Announces Closing of Public Offering

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the closing of its previously announced offering of

RHEA-AI

neutral

10/15/20 8:30 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S.

RHEA-AI

neutral

10/14/20 8:30 AM

Nasdaq : ETON

offeringlow float

Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000

RHEA-AI

neutral

10/13/20 4:01 PM

Nasdaq : ETON

offeringlow float

Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in

RHEA-AI

neutral

10/08/20 8:00 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals, Inc

RHEA-AI

very positive

10/06/20 4:05 PM

Nasdaq : ETON

low float

Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate - Topiramate Oral Solution is Eton’s Third Neurology Product Candidate Submitted to the FDA DEER PARK, Ill., Oct.

RHEA-AI

very positive

09/29/20 6:49 PM

Nasdaq : ETON

fda approvallow float

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency

RHEA-AI

very positive

09/29/20 6:49 PM

Nasdaq : ETON

fda approvallow float

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency

RHEA-AI

very positive

09/25/20 8:00 AM

NYSE, Nasdaq : BHC, ETON

fda approval

FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA) has

RHEA-AI

positive

09/16/20 9:00 AM

Nasdaq : ETON

low float

Eton Pharmaceuticals Provides Update on the FDA Review of EM-100

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported that its partner has not yet received a communication from the U.S. Food and Drug

RHEA-AI

neutral

Prev 1 2 3 4 5 Next